A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (VISION-AF)

March 4, 2024 updated by: Bayer

A Phase IV Interventional Post Approval Trial to Assess the Safety of Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (DME) in Patients in India.

Researchers are looking for a better way to treat people who have diabetic macular edema (DME).

Diabetic macular edema (DME) is a complication of diabetes. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Damaged blood vessels in the eye may lead to leakage of the fluid into the central part of the retina at the back of the eye (also called macula) where sharp, straight-ahead vision occurs. Fluid accumulation makes the macula swell and results in reduced vision. If not treated, DME can result in complete loss of central detailed vision.

The study treatment intravitreal aflibercept (also called BAY865321) works by blocking VEGFR-1 receptor activity. Intravitreal aflibercept is already approved in over 105 countries for doctors to prescribe to people with DME. In India, aflibercept is approved conditionally for people with DME. The reason for this is that the sponsor was asked to collect more safety data for intravitreal aflibercept in Indian people with DME.

The main purpose of this study is to collect more data to learn how safe intravitreal aflibercept is in Indian people with DME. To see how safe intravitreal aflibercept is, the researchers will collect the information/data on the medical problems the participants may have during the study, and which may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AEs). AEs will be categorized according to relatedness, seriousness, discontinuation of therapy, action taken and outcome.

The study participants will receive aflibercept as an injection directly into the space in the back of the eye once every 4 weeks in the first 5 months, followed by one injection every 8 weeks for the rest of the study duration. Only one eye per participant to be treated with aflibercept will be considered for the study.

Each participant will be in the study for approximately 52 weeks. The treatment duration will be 48 weeks. For each participant 11 visits to the study site are planned. The study team will perform additional safety calls 16 to 36 hours after each visit starting at visit 2. Alternatively, an additional safety visit can be arranged/planned for the day after treatment.

During the study, the study team will:

  • take blood and urine samples
  • examine the participants' eyes
  • do physical examinations
  • examine heart health using ECG
  • check vital signs
  • ask the participants questions about how they are feeling and what adverse events they are having.
  • in- administer the study drug

At the end of the study the participants will be switched to commercially available treatment if recommended by the study doctor/if the participant still benefits from the treatment.

Study Overview

Status

Active, not recruiting

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Chandigarh, India, 160012
        • Post Graduate Institute of Medical Education and Research
    • Andhra Pradesh
      • Hyderabad, Andhra Pradesh, India, 500034
        • L.V. Prasad Eye Institute
    • Delhi
      • New Delhi, Delhi, India, 110029
        • Dr. R.P. Centre for Ophthalmic Sciences, AIIMS
    • Gujarat
      • Ahmedabad, Gujarat, India, 380016
        • M & J Western Regional Institute of Ophthalmology
      • Ahmedabad, Gujarat, India, 380052
        • Raghudeep Eye Hospital
    • Karnataka
      • Bengaluru, Karnataka, India, 560037
        • Sankara Eye Hospital
      • Bengaluru, Karnataka, India, 560010
        • Narayana Nethralaya
    • Tamil Nadu
      • Chennai, Tamil Nadu, India, 600006
        • Medical Research Foundation, Sankara Nethralaya
      • Coimbatore, Tamil Nadu, India, 641014
        • Lotus Eye Hospital and Institute
    • West Bengal
      • Kolkata, West Bengal, India, 700120
        • Disha Eye Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female or male adult participant ≥18 years of age, with type 1 or 2 diabetes mellitus.
  • Participant must have diabetic macular edema (DME) secondary to diabetes mellitus, involving the centre of the macula (defined as the area of the centre subfield of optical coherence tomography (OCT)) in the study eye.
  • Decrease in vision, determined to be primarily the result of DME in the study eye.
  • Retinal thickness of ≥300 µm in the study eye, as assessed by OCT.
  • Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study ( ETDRS) letter score of 73 to 24 (i.e., VA of 20/50 to 20/320) or equivalent in the study eye.
  • Participant for whom the decision to initiate treatment with Intravitreal (IVT) aflibercept has been made by the treating Investigator/Physician.
  • Willing and able to comply with clinic visits and study-related procedures.
  • Provide a signed Informed Consent Form (ICF) prior to any study procedures.

Exclusion Criteria:

  • Having any contraindications to the use of IVT aflibercept as listed in the local prescribing information (i.e., ocular or periocular infection, active severe intraocular inflammation, and known hypersensitivity to aflibercept or to any of the excipients).
  • History of vitreoretinal surgery and/or scleral buckling in the study eye.
  • Ocular conditions with a poorer prognosis in the fellow eye than in the study eye.
  • Received previous/ prior treatment as mentioned below:

    • Received anti-Vascular Endothelial Growth Factor (VEGF) drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc., including aflibercept) within the last 3 months of Day 1.
    • Received IVT dexamethasone or triamcinolone in the study eye within the last 3 months of Day 1.
    • Received intraocular or periocular corticosteroids in the study eye within the last 4 months of Day 1.
    • Had fluocinolone implant in the study eye within the last 3 years of Day 1.
    • Had dexamethasone implant in the study eye within the last 6 months of Day 1.
    • systemic anti-angiogenic agents within 6 months of Day 1.
  • Uncontrolled glaucoma in the study eye (patient who has had filtration surgery in the past, or likely to need filtration surgery in the future).
  • Only 1 functional eye even if that eye is otherwise eligible for the study.
  • Participated in an investigational study within 30 days prior to screening visit that involved treatment with any drug (excluding vitamins and minerals) or device.
  • Pregnant or breast-feeding women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aflibercept
Participants will receive one aflibercept injection per month (every four weeks) for five consecutive doses, followed by one injection every alternate month (every 8 weeks) for rest of the duration
Injection, 2mg (equivalent to 50 µL solution for injection)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of ocular and non-ocular treatment-emergent adverse events (TEAEs)
Time Frame: At week 52
At week 52

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in best corrected visual acuity (BCVA)
Time Frame: From baseline to week 52
BCVA is assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or equivalent.
From baseline to week 52
Change in central retinal thickness (CRT)
Time Frame: From baseline to week 52
CRT is measured by optical coherence tomography (OCT), Fluorescein Angiography (FA).
From baseline to week 52
Proportion of eyes that gain ≥ 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters
Time Frame: From baseline to week 52
From baseline to week 52
Proportion of eyes with a ≥2 step improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score
Time Frame: From baseline to week 52
From baseline to week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 26, 2022

Primary Completion (Estimated)

April 30, 2024

Study Completion (Estimated)

April 30, 2024

Study Registration Dates

First Submitted

August 19, 2022

First Submitted That Met QC Criteria

August 19, 2022

First Posted (Actual)

August 22, 2022

Study Record Updates

Last Update Posted (Estimated)

March 5, 2024

Last Update Submitted That Met QC Criteria

March 4, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Macular Edema

Clinical Trials on Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

3
Subscribe